Solid Biosciences Llc Stock Performance
| SLDB Stock | USD 6.19 0.11 1.81% |
On a scale of 0 to 100, Solid Biosciences holds a performance score of 12. The entity has a beta of 1.98, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Solid Biosciences will likely underperform. Please check Solid Biosciences' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Solid Biosciences' existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Solid Biosciences LLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Solid Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.81 | Five Day Return (3.28) | Year To Date Return 13.58 | Ten Year Return (98.18) | All Time Return (98.18) |
Last Split Factor 1:15 | Last Split Date 2022-10-28 |
1 | Disposition of 72 shares by Paul Herzich of Solid Biosciences subject to Rule 16b-3 | 12/02/2025 |
2 | Disposition of 2701 shares by Paul Herzich of Solid Biosciences at 5.11 subject to Rule 16b-3 | 12/03/2025 |
3 | Acquisition by Smith Ian F of 13761 shares of Solid Biosciences subject to Rule 16b-3 | 01/02/2026 |
4 | Disposition of 4573 shares by Smith Ian F of Solid Biosciences subject to Rule 16b-3 | 01/06/2026 |
5 | Acquisition by Smith Ian F of 4573 shares of Solid Biosciences subject to Rule 16b-3 | 01/07/2026 |
6 | Disposition of 11250 shares by Tan Kevin of Solid Biosciences subject to Rule 16b-3 | 01/09/2026 |
7 | Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreichs At... | 01/12/2026 |
8 | Will KROS Stocks Restructuring Efforts Reap Rewards for Investors | 01/16/2026 |
9 | Disposition of 3884 shares by Ilan Ganot of Solid Biosciences subject to Rule 16b-3 | 01/27/2026 |
10 | Disposition of 191 shares by Ilan Ganot of Solid Biosciences at 6.59 subject to Rule 16b-3 | 01/28/2026 |
11 | Acquisition by Ilan Ganot of 35450 shares of Solid Biosciences subject to Rule 16b-3 | 01/29/2026 |
12 | Disposition of 26250 shares by Paul Herzich of Solid Biosciences at 6.4369 subject to Rule 16b-3 | 02/02/2026 |
13 | Disposition of 10905 shares by Paul Herzich of Solid Biosciences at 6.4419 subject to Rule 16b-3 | 02/04/2026 |
14 | Solid Biosciences to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 | 02/06/2026 |
15 | Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy | 02/09/2026 |
| Begin Period Cash Flow | 75.8 M | |
| Total Cashflows From Investing Activities | -16.1 M |
Solid Biosciences Relative Risk vs. Return Landscape
If you would invest 434.00 in Solid Biosciences LLC on November 16, 2025 and sell it today you would earn a total of 185.00 from holding Solid Biosciences LLC or generate 42.63% return on investment over 90 days. Solid Biosciences LLC is currently generating 0.6788% in daily expected returns and assumes 4.4752% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Solid, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Solid Biosciences Target Price Odds to finish over Current Price
The tendency of Solid Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.19 | 90 days | 6.19 | about 22.02 |
Based on a normal probability distribution, the odds of Solid Biosciences to move above the current price in 90 days from now is about 22.02 (This Solid Biosciences LLC probability density function shows the probability of Solid Stock to fall within a particular range of prices over 90 days) .
Solid Biosciences Price Density |
| Price |
Predictive Modules for Solid Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Solid Biosciences LLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Solid Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Solid Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Solid Biosciences is not an exception. The market had few large corrections towards the Solid Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Solid Biosciences LLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Solid Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.58 | |
β | Beta against Dow Jones | 1.98 | |
σ | Overall volatility | 0.70 | |
Ir | Information ratio | 0.14 |
Solid Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Solid Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Solid Biosciences LLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Solid Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (96.43 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (100.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Solid Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy |
Solid Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Solid Stock often depends not only on the future outlook of the current and potential Solid Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Solid Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.8 M | |
| Cash And Short Term Investments | 148.9 M |
Solid Biosciences Fundamentals Growth
Solid Stock prices reflect investors' perceptions of the future prospects and financial health of Solid Biosciences, and Solid Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Solid Stock performance.
| Return On Equity | -0.87 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 284.03 M | ||||
| Shares Outstanding | 77.91 M | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (96.43 M) | ||||
| EBITDA | (121.9 M) | ||||
| Net Income | (124.7 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 24.18 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 2.80 X | ||||
| Cash Flow From Operations | (100.01 M) | ||||
| Earnings Per Share | (2.35) X | ||||
| Market Capitalization | 473.69 M | ||||
| Total Asset | 188.66 M | ||||
| Retained Earnings | (783.45 M) | ||||
| Working Capital | 127.05 M | ||||
About Solid Biosciences Performance
By analyzing Solid Biosciences' fundamental ratios, stakeholders can gain valuable insights into Solid Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Solid Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Solid Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (0.94) | (0.99) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (1.04) | (0.99) |
Things to note about Solid Biosciences LLC performance evaluation
Checking the ongoing alerts about Solid Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Solid Biosciences LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Solid Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (96.43 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (100.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Solid Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy |
- Analyzing Solid Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Solid Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Solid Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Solid Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Solid Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Solid Biosciences' stock. These opinions can provide insight into Solid Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |